ACOT7

Across TCGA pan-cancer cohorts, ACOT7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACOT7 data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ACOT7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACOT7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where ACOT7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.949	0.766	.006	20	view →
CCRCC	OS	Median	III,IV	0.722	0.939	.017	7	view →
LUAD	DFS	Tertile	II,III,IV	0.994	0.753	.015	6	view →
PDAC	OS	Quartile	II,III,IV	0.573	0.277	.018	5	view →
GBM	DFS	Tertile	All	0.843	0.665	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACOT7–HNSC (OS)

Open the HNSC breakdown →